COST

1,026.04

+1.58%↑

PG

163.23

+0.5%↑

KO

71.99

+0.52%↑

PM

170.34

+0.66%↑

PEP

131.96

+0.43%↑

COST

1,026.04

+1.58%↑

PG

163.23

+0.5%↑

KO

71.99

+0.52%↑

PM

170.34

+0.66%↑

PEP

131.96

+0.43%↑

COST

1,026.04

+1.58%↑

PG

163.23

+0.5%↑

KO

71.99

+0.52%↑

PM

170.34

+0.66%↑

PEP

131.96

+0.43%↑

COST

1,026.04

+1.58%↑

PG

163.23

+0.5%↑

KO

71.99

+0.52%↑

PM

170.34

+0.66%↑

PEP

131.96

+0.43%↑

COST

1,026.04

+1.58%↑

PG

163.23

+0.5%↑

KO

71.99

+0.52%↑

PM

170.34

+0.66%↑

PEP

131.96

+0.43%↑

Search

Hims & Hers Health Inc

Suletud

SektorTarbekaubad (kaitseaktsiad)

64.47 10.15

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

57.38

Max

64.77

Põhinäitajad

By Trading Economics

Sissetulek

23M

49M

Müük

105M

586M

P/E

Sektori keskmine

81.191

42.52

Aktsiakasum

0.2

Kasumimarginaal

8.444

Töötajad

1,637

EBITDA

39M

58M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

-25.56% downside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

4. aug 2025

Turustatistika

By TradingEconomics

Turukapital

3.2B

12B

Eelmine avamishind

54.32

Eelmine sulgemishind

64.47

Uudiste sentiment

By Acuity

20%

80%

16 / 151 Pingereas Consumer defensive

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Hims & Hers Health Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. apr 2025, 12:54 UTC

Suurimad hinnamuutused turgudel

Hims & Hers Rallies After Novo Nordisk Deal on Wegovy

4. apr 2025, 22:38 UTC

Kuumad aktsiad

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

1. apr 2025, 23:15 UTC

Suurimad hinnamuutused turgudel

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

25. veebr 2025, 15:33 UTC

Suurimad hinnamuutused turgudel

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

18. nov 2024, 19:07 UTC

Suurimad hinnamuutused turgudel

Hims & Hers Stock Climbs After Former Regulator Autor Joins Board

14. okt 2024, 15:02 UTC

Suurimad hinnamuutused turgudel

Hims & Hers Health Shares Jump After FDA Set to Reconsider Limits on Knockoff Weight-Loss Drugs

3. okt 2024, 11:28 UTC

Suurimad hinnamuutused turgudel

Hims & Hers Health Shares Fall After FDA Removes Eli Lilly Obesity Drugs From Shortage List

7. mai 2025, 13:56 UTC

Tulu

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

6. mai 2025, 14:24 UTC

Tulu

Hims & Hers Stock Is Higher After Earnings. The Sales Outlook Looks Low. -- Barrons.com

30. apr 2025, 09:30 UTC

Peamised uudised

Why New Wegovy Deals Won't Restore Novo's Obesity Lead -- Heard on the Street -- WSJ

2. apr 2025, 16:53 UTC

Peamised uudised

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

19. märts 2025, 15:54 UTC

Peamised uudised

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

21. veebr 2025, 23:20 UTC

Tulu

These Stocks Moved the Most Today: UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More -- Barrons.com

10. veebr 2025, 12:00 UTC

Peamised uudised

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

19. dets 2024, 17:16 UTC

Peamised uudised

FDA Says Shortage of Eli Lilly's Zepbound is Over, But Gives Compounders a Grace Period -- Barrons.com

19. dets 2024, 15:14 UTC

Peamised uudised

Eli Lilly's Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

19. dets 2024, 15:02 UTC

Peamised uudised

The Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

16. dets 2024, 13:47 UTC

Peamised uudised

The Weight-Loss Drug Market Is Heading for a Reckoning This Week -- Barrons.com

16. dets 2024, 07:00 UTC

Peamised uudised

The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect. -- Barrons.com

3. okt 2024, 14:45 UTC

Peamised uudised

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

3. okt 2024, 13:12 UTC

Peamised uudised

Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3. okt 2024, 11:45 UTC

Peamised uudised

Update: Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3. okt 2024, 10:14 UTC

Peamised uudised

Update: Eli Lilly's Weight-Loss Drugs No Longer In Shortage. It's Bad News for These Stocks. -- Barrons.com

2. aug 2024, 17:52 UTC

Omandamised, ülevõtmised, äriostud

Hims & Hers Plan to Sell Knockoff Weight Loss Drug Looking Shaky -- Barrons.com

26. juuni 2024, 11:00 UTC

Peamised uudised
Omandamised, ülevõtmised, äriostud

The War Over Cheaper Ozempic Won't End Well for Some Investors -- Heard on the Street -- WSJ

24. mai 2024, 20:37 UTC

Tulu

The Score: Target, Nvidia, Live Nation and More Stocks That Defined the Week -- WSJ

Võrdlus sarnastega

Hinnamuutus

Hims & Hers Health Inc Prognoos

Hinnasiht

By TipRanks

-25.56% langus

12 kuu keskmine prognoos

Keskmine 45.5 USD  -25.56%

Kõrge 85 USD

Madal 25 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Hims & Hers Health Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

14 ratings

4

Osta

8

Hoia

2

Müü

Tehniline skoor

By Trading Central

36.685 / 52.35Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

16 / 151 Pingereas Tarbekaubad (kaitseaktsiad)

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Hims & Hers Health Inc

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.